Identification | Back Directory | [Name]
Benzamide, 3-methoxy-N-[4-(4-methoxyphenyl)-2-thiazolyl]-4-[2-(4-morpholinyl)-2-oxoethoxy]- | [CAS]
781628-99-7 | [Synonyms]
Benzamide, 3-methoxy-N-[4-(4-methoxyphenyl)-2-thiazolyl]-4-[2-(4-morpholinyl)-2-oxoethoxy]- | [Molecular Formula]
C24H25N3O6S | [MDL Number]
MFCD04508832 | [MOL File]
781628-99-7.mol | [Molecular Weight]
483.54 |
Chemical Properties | Back Directory | [density ]
1.331±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 65 mg/mL (134.43 mM) | [form ]
Solid | [pka]
7.14±0.50(Predicted) | [color ]
Light yellow to yellow |
Hazard Information | Back Directory | [Uses]
SBI-477 is a chemical probe stimulated insulin signaling by deactivating the transcription factor MondoA, leading to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain–containing 4 (ARRDC4). SBI-477 coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes[1]. | [References]
[1] Ahn B, et al. MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J Clin Invest. 2016 Sep 1;126(9):3567-79. DOI:10.1172/JCI87382 |
|
|